Results 31 to 40 of about 18,295 (182)

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

Monodentate Phosphine Modulation in Cyclometallated Platinum(II) Complexes for Antileishmanial, Antiviral, and Antitumor Applications

ChemMedChem, EarlyView.
Schematic representation depicting the influence of phosphine ligand identity on the biological and physicochemical characteristics of Pt(II) complexes: PTA promotes antileishmanial activity, PPh2(Php–COOH) strengthens antiviral activity, and TCEP enhances fluorescence.
Antonio A. de Oliveira‐Neto, Gustavo Clauss, Jennyfer Castro, Marcus S. A. Garcia, Natasha M. Cassani, Bruna C. Sandim, Ana Laura C. Oliveira, Stephanie P. B. Reyes, Nádija N. P. da Silva, Fillipe V. Rocha, Ana C. G. Jardim, Danilo C. Miguel, Camilla Abbehausen   +12 more
wiley   +1 more source

Treatment of Visceral Leishmaniasis

Archives of Pediatrics & Adolescent Medicine, 1992
Sir .—Mahieu and Van Acker 1 reported a case of visceral leishmaniasis (kalaazar) in the November 1991 issue of AJDC . Several case reports were included in the references, but only a few were from Mediterranean countries in which the disease is more prevalent, as mentioned by the authors. I would like to bring our experience with this disease into the
openaire   +3 more sources

Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post‐Kala‐Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing

Clinical Pharmacology &Therapeutics, EarlyView.
Post‐kala‐azar dermal leishmaniasis (PKDL) involves a high macrophage burden in which the Leishmania parasites reside. Liposomal amphotericin B (LAmB) plays a key role in the treatment of PKDL. The mononuclear phagocyte system (MPS) is crucial in the distribution of liposomal drugs as well as the leishmaniasis pathophysiology.
Wan‐Yu Chu, Om Prakash Singh, Shyam Sundar, Dinesh Mondal, Krishna Pandey, Pradeep Das, Ignace C. Roseboom, Sheeraz Raja, Ana Torres, Eugenia Carrillo, Alwin D.R. Huitema, Fabiana Alves, Thomas P.C. Dorlo   +12 more
wiley   +1 more source

Harnessing controlled human infection models to accelerate vaccine development for neglected tropical diseases: Lessons from leishmaniasis

European Journal of Clinical Investigation, EarlyView.
Controlled Human Infection Models (CHIMs) offer a powerful approach to accelerate vaccine development for neglected tropical diseases (NTDs). This review highlights scientific and translational advances enabled by CHIMs, with a focus on a novel Leishmania major model.
Vivak Parkash
wiley   +1 more source

Leishmania donovani's protein tyrosine phosphatases interact with DUF21 and respond to environmental magnesium

The FEBS Journal, EarlyView.
The Leishmania phosphatase PTP1, and possibly the genetically similar PTP2, interacts with the Leishmania transmembrane protein DUF21. When both ptp1 and ptp2 are knocked out of Leishmania (LdΔPTP1/2), the parasite can no longer survive without magnesium in vitro and has reduced viability in the host macrophage. Conversely, in duf21 knockout (LdΔDUF21),
Kayla Paulini, Hira Khursheed, Wen Wei Zhang, Isabelle Aubry, Greg Matlashewski, Michel L. Tremblay, Patrick Lypaczewski   +6 more
wiley   +1 more source

Treatment of visceral leishmaniasis [PDF]

International Journal of Infectious Diseases, 2001
Growing antimony resistance in patients with visceral leishmaniasis (VL) over last two decades, especially in Indian subcontinent, renders this cheap and easily available drug useless for a vast majority of patients. Use of the second line drug pentamidine isethionate, a toxic drug with declining efficacy, has largely been abandoned.
openaire   +2 more sources

Artificial intelligence‐powered microscopy: Transforming the landscape of parasitology

Journal of Microscopy, EarlyView.
Abstract Microscopy and image analysis play a vital role in parasitology research; they are critical for identifying parasitic organisms and elucidating their complex life cycles. Despite major advancements in imaging and analysis, several challenges remain. These include the integration of interdisciplinary data; information derived from various model
Mariana De Niz, Sara Silva Pereira, David Kirchenbuechler, Leandro Lemgruber, Constadina Arvanitis   +4 more
wiley   +1 more source

Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)

Therapeutics and Clinical Risk Management, 2012
Viroj Wiwanitkit1–31Wiwanitkit House, Bang Khae, Bangkok, Thailand; 2Hainan Medical University, Haikou, Hainan, People's Republic of China; 3Joseph Ayo Babalola University, Ikeji-Arakeji, Osun State, NigeriaAbstract: Leishmaniasis is an
Wiwanitkit V
doaj  

Simultaneous Occurrence of Ocular, Disseminated Mucocutaneous, and Multivisceral Involvement of Leishmaniasis

Case Reports in Infectious Diseases, 2014
Leishmaniasis is a tropical infection caused by the protozoan, belonging to the group of Leishmania which causes Old World and New World disease. These are typically divided into cutaneous, mucocutaneous, visceral, viscerotropic, and disseminated disease.
Cyriac Abby Philips, Chetan Ramesh Kalal, K. N. Chandan Kumar, Chhagan Bihari, Shiv Kumar Sarin   +4 more
doaj   +1 more source